Phylecya Cheatham, MD
Family Medicine · Troy, ALNPI 1952326704
Payments from drug & device makers
Across 165 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$738
- Lilly USA, LLC$508
- Astellas Pharma US Inc$323
- AstraZeneca$211
- AbbVie$114
- Merck$114
- plus $875 from 23 others
What the payments were for
- Food & beverage$2,64892%
- Education$2358%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $738 |
| Lilly USA, LLC | 34 | $508 |
| Astellas Pharma US Inc | 8 | $323 |
| AstraZeneca | 13 | $211 |
| AbbVie(2 entities) | 7 | $114 |
| Merck | 8 | $114 |
| Bayer | 4 | $94 |
| Pfizer | 6 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $77 |
| Exact Sciences | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $69 |
| Amgen | 4 | $65 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| GSK | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Alkermes, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Lupin Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Novartis | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Emmaus Medical, Inc. | 1 | $12 |
| Linus Health, Inc. | 1 | $12 |
How this compares
$2,883 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $148,847 |
| MounjaroTirzepatide | 123 | $137,029 |
| JardianceEmpagliflozin | 95 | $121,041 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $78,933 |
| LinzessLinaclotide | 71 | $62,808 |
| FarxigaDapagliflozin Propanediol | 61 | $54,265 |
| EliquisApixaban | 45 | $41,795 |
| EntrestoSacubitril/Valsartan | 27 | $29,502 |
| TrulicityDulaglutide | 22 | $27,521 |
| MyrbetriqMirabegron | 32 | $26,658 |
| XareltoRivaroxaban | 29 | $25,190 |
| JanuviaSitagliptin Phosphate | 26 | $24,467 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $21,592 |
| CaplytaLumateperone Tosylate | 12 | $18,663 |
| Glatiramer Acetate | 12 | $17,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $508 | $164,550145 claims |
| Novo NordiskOzempic | $738 | $148,847114 claims |
| Boehringer IngelheimJardiance | $14 | $121,04195 claims |
| AbbVieLinzess, Qulipta | $114 | $76,16683 claims |
| AstraZenecaFarxiga, Symbicort | $211 | $57,17875 claims |
| MerckJanuvia, Janumet Xr, Steglatro | $114 | $42,11951 claims |
| PfizerEliquis | $92 | $41,79545 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $34 | $31,61558 claims |
| NovartisEntresto | $13 | $29,50227 claims |
| Astellas Pharma US IncMyrbetriq | $323 | $26,65832 claims |
| Johnson & JohnsonXarelto | $18 | $25,19029 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $77 | $18,66312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Troy
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.